Singapore-based venture debt provider Genesis Alternative Ventures has secured an investment of undisclosed size for its debut fund from US-based Capria Ventures.
Genesis was established last year by Jeremy Loh and Martin Tang, both formerly of the venture debt unit at DBS Bank, and Ben Benjamin, an angel investor and non-executive director at OurCrowd Singapore....
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.